New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
11:11 EDTARIA, ICPT, EXEL, CREE, YRCWOptions with decreasing implied volatility: ICPT YRCW EXEL ARIA CREE
News For ICPT;YRCW;EXEL;ARIA;CREE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 26, 2015
14:45 EDTICPTIntercept's risk/reward remains favorable, says Citigroup
Subscribe for More Information
13:04 EDTICPTIntercept rallies after GENFIT announces NASH study results
GENFIT announced topline results of the phase 2 GOLDEN-505 trial in NASH. It stated, "Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint. With correction for this baseline severity and site heterogeneity by a standardized statistical analysis, GFT505 120mg meets the primary endpoint: Reversal on NASH without worsening of fibrosis, as detailed below." Treatment with GFT505 provides a significant beneficial effect on the primary endpoint in the global randomized population, where patients without an end of treatment biopsy were considered as non-responders, GENFIT added. The primary endpoint was also achieved in the evaluable population of patients who underwent both baseline and end of study liver biopsies. Shares of Intercept, which is also developing a NASH treatment, jumped 7%, or $18.06 to $278.70.
12:56 EDTICPTIntercept jumps after Genfit says NASH drug missed endpoint in Phase 2 study
Subscribe for More Information
10:56 EDTCREEOptions with increasing implied volatility
Subscribe for More Information
March 25, 2015
16:55 EDTICPTOrbiMed Advisors lowers stake in Intercept to 5.64% from 7.0%
10:51 EDTCREEOptions with increasing implied volatility
Options with increasing implied volatility: CLDN CMG CREE AMZN ISRG MAC UA VMW SLXP
09:29 EDTARIAARIAD reports dismissal of class action suit in federal district court
ARIAD Pharmaceuticals announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy. The suit alleged that certain of the company defendants made a series of false and misleading statements regarding the safety, efficacy and commercial prospects of Iclusig. The Court granted the company’s motion to dismiss the lawsuit, concluding that the plaintiffs failed to establish that any such statements violated the company’s disclosure obligations as asserted in the complaint. “We are pleased that for the second time in as many weeks, the Court has granted our motion to dismiss what we believed from the outset was another meritless lawsuit,” said Harvey J. Berger, M.D., chairman and CEO. “Our corporate values of integrity and mutual respect are always at the forefront as we continue to focus on executing our plan for sustained revenue growth and operational excellence, leading to anticipated profitability in 2018.”
March 24, 2015
10:40 EDTCREEOptions with increasing implied volatility
Subscribe for More Information
10:32 EDTCREEOptions with increasing implied volatility
Options with increasing implied volatility: MAC CMG HLSS PSEC ISRG AMZN CREE
09:22 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:37 EDTARIAARIAD announces approval of Iclusig in Israel
ARIAD Pharmaceuticals and Medison Pharma announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig, ponatinib, in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of Iclusig is expected to occur in Q2.
March 23, 2015
07:22 EDTICPTIntercept price target raised to $265 from $205 at Leerink
Subscribe for More Information
March 20, 2015
09:24 EDTICPTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Ctrip.com (CTRP), up 20.1%... Rally Software (RALY), up 17.3%... Nike (NKE), up 5.2%... Darden Restaurants (DRI), up 4.3%... Cheetah Mobile (CMCM), up 3.6%. ALSO HIGHER: Prothena (PRTA), up 40.2% after reporting positive results from Phase 1 study of PRX002... Viggle (VGGL), up 26.9% after confirming receipt of offer from chairman and CEO Robert Sillerman... Intercept Pharmaceuticals (ICPT), up 8.5% after announcing new data analyses from FLINT trial... Biogen Idec (BIIB), up 9.7% after presenting positive interim results from study of aducanumab... Pier 1 Imports (PIR), up 5.2% after being upgraded to Outperform from Perform at Oppenheimer... JinkoSolar (JKS), up 2.8% after announcing that it will supply 75 MWdc of its PV solar modules to Red Horse 2 project and following a strategic collaboration agreement with DuPont (DD). DuPont is up just under 1%. DOWN AFTER EARNINGS: AK Steel (AKS), down 6.8%... Youku Tudou (YOKU), down 4.9%... Tiffany (TIF), down 3.3%. ALSO LOWER: Macerich (MAC), down 7.7% after Simon makes $95.50 per share "best and final" offer.
06:02 EDTICPTIntercept announces new data analyses from FLINT trial
Subscribe for More Information
March 19, 2015
13:07 EDTICPTIntercept to host analyst and investor meeting
Subscribe for More Information
March 18, 2015
09:00 EDTICPTIntercept price target raised to $344 from $258 at RW Baird
Subscribe for More Information
March 17, 2015
10:00 EDTICPTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aimco (AIV) initiated with an Outperform at RW Baird... Alnylam (ALNY) initiated with a Buy at Janney Capital... American Campus (ACC) initiated with a Neutral at RW Baird... AvalonBay (AVB) initiated with a Neutral at RW Baird... BE Aerospace (BEAV) initiated with a Buy at CRT Capital... BlackRock (BLK) initiated with a Buy at Argus... Camden Property (CPT) initiated with an Outperform at RW Baird... CarMax (KMX) initiated with a Buy at Evercore ISI... Central Pacific (CPF) initiated with a Neutral at Macquarie... Cognex (CGNX) initiated with a Buy at Northcoast... Education Realty (EDR) initiated with a Neutral at RW Baird... EnerSys (ENS) initiated with an Overweight at Stephens... Equity Lifestyle (ELS) initiated with an Outperform at RW Baird... Equity Residential (EQR) initiated with a Neutral at RW Baird... Essex Property Trust (ESS) initiated with a Neutral at RW Baird... Facebook (FB) initiated with a Buy at Brean Capital... Intercept (ICPT) initiated with a Hold at MLV & Co.... Isis Pharmaceuticals (ISIS) initiated with a Neutral at Janney Capital... LinkedIn (LNKD) initiated with a Sell at Brean Capital... Mid-America Apartment (MAA) initiated with an Outperform at RW Baird... NetSuite (N) initiated with a Hold at Brean Capital... Paycom (PAYC) initiated with a Buy at Brean Capital... Platform Specialty Products (PAH) initiated with a Buy at UBS... Post Properties (PPS) initiated with a Neutral at RW Baird... Salesforce.com (CRM) initiated with a Hold at Brean Capital... ServiceNow (NOW) initiated with a Buy at Brean Capital... Snap-On (SNA) initiated with a Buy at Northcoast... Sun Communities (SUI) initiated with a Neutral at RW Baird... Twitter (TWTR) initiated with a Buy at Brean Capital... UDR, Inc. (UDR) initiated with an Outperform at RW Baird... Workday (WDAY) initiated with a Hold at Brean Capital... Xplore Technologies (XPLR) initiated with a Buy at Roth Capital... Yahoo (YHOO) initiated with a Hold at Argus.
06:18 EDTICPTIntercept initiated with a Hold at MLV & Co.
Subscribe for More Information
05:55 EDTCREELEDinside: LED industrial market to reach $2.37B in 2015, DigiTimes says
Subscribe for More Information
March 13, 2015
13:27 EDTARIAARIAD drug granted orphan designation as GIST treatment
ARIAD Pharmaceuticals' Iclusig was granted FDA orphan status on February 12 as a treatment of gastrointestinal stromal tumors, or GIST, according to a post to the agency's site. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use